%0 Journal Article %1 Gallo2006 %A Gallo, Paul %A Chuang-Stein, Christy %A Dragalin, Vladimir %A Gaydos, Brenda %A Krams, Michael %A Pinheiro, José %D 2006 %J Journal of biopharmaceutical statistics %K BiomedicalResearch ClinicalTrialsDataMonitoringCommittees ClinicalTrialsasTopic ClinicalTrialsasTopic:methods ClinicalTrialsasTopic:standards DataInterpretation Dose-ResponseRelationship Drug DrugIndustry DrugIndustry:standards GuidelinesasTopic Humans ResearchDesign SampleSize Statistical UnitedStates UnitedStatesFoodandDrugAdministration UnitedStatesFoodandDrugAdministration:standa %N 3 %P 275-83; discussion 285-91, 293-8, 311-2 %R 10.1080/10543400600614742 %T Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group. %U http://www.ncbi.nlm.nih.gov/pubmed/16724485 %V 16 %X A PhRMA Working Group on adaptive clinical trial designs has been formed to investigate and facilitate opportunities for wider acceptance and usage of adaptive designs and related methodologies. A White Paper summarizing the findings of the group is in preparation; this article is an Executive Summary for that full White Paper, and summarizes the findings and recommendations of the group. Logistic, operational, procedural, and statistical challenges associated with adaptive designs are addressed. Three particular areas where it is felt that adaptive designs can be utilized beneficially are discussed: dose finding, seamless Phase II/III trials designs, and sample size reestimation. %@ 1054-3406

@article{Gallo2006, abstract = {A PhRMA Working Group on adaptive clinical trial designs has been formed to investigate and facilitate opportunities for wider acceptance and usage of adaptive designs and related methodologies. A White Paper summarizing the findings of the group is in preparation; this article is an Executive Summary for that full White Paper, and summarizes the findings and recommendations of the group. Logistic, operational, procedural, and statistical challenges associated with adaptive designs are addressed. Three particular areas where it is felt that adaptive designs can be utilized beneficially are discussed: dose finding, seamless Phase II/III trials designs, and sample size reestimation.}, added-at = {2023-02-03T11:44:35.000+0100}, author = {Gallo, Paul and Chuang-Stein, Christy and Dragalin, Vladimir and Gaydos, Brenda and Krams, Michael and Pinheiro, José}, biburl = {https://www.bibsonomy.org/bibtex/28450cd4ae8baaf105b7be8fa1b826399/jepcastel}, city = {Novartis Pharmaceuticals, East Hanover, NJ 07936, USA. paul.gallo@novartis.com}, doi = {10.1080/10543400600614742}, interhash = {c3953dea678d75e136a94ef10cf06dda}, intrahash = {8450cd4ae8baaf105b7be8fa1b826399}, isbn = {1054-3406}, issn = {1054-3406}, journal = {Journal of biopharmaceutical statistics}, keywords = {BiomedicalResearch ClinicalTrialsDataMonitoringCommittees ClinicalTrialsasTopic ClinicalTrialsasTopic:methods ClinicalTrialsasTopic:standards DataInterpretation Dose-ResponseRelationship Drug DrugIndustry DrugIndustry:standards GuidelinesasTopic Humans ResearchDesign SampleSize Statistical UnitedStates UnitedStatesFoodandDrugAdministration UnitedStatesFoodandDrugAdministration:standa}, month = {5}, note = {5002<br/>LR: 20071115; JID: 9200436; CIN: J Biopharm Stat. 2006 May;16(3):299-309; discussion 311-2. PMID: 16724486; ppublish;<br/>Tipus d'estudis; Dissenys adaptatius}, number = 3, pages = {275-83; discussion 285-91, 293-8, 311-2}, pmid = {16724485}, timestamp = {2023-02-03T11:44:35.000+0100}, title = {Adaptive designs in clinical drug development--an Executive Summary of the PhRMA Working Group.}, url = {http://www.ncbi.nlm.nih.gov/pubmed/16724485}, volume = 16, year = 2006 }